LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 2 | O20 | 72 | hr | 2543 | 4355 | 5578 | 0.7807 | 0.5968 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 3 | O20 | 72 | hr | 2543 | 4895 | 5578 | 0.8775 | 0.7748 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP5 | 1 | C20 | 72 | hr | 2543 | 1217 | 5578 | 0.2182 | -0.4370 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP5 | 2 | C20 | 72 | hr | 2543 | 1253 | 5578 | 0.2246 | -0.4252 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP5 | 3 | C20 | 72 | hr | 2543 | 1456 | 5578 | 0.2610 | -0.3583 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP6 | 1 | C20 | 72 | hr | 2543 | 910 | 5578 | 0.1631 | -0.5382 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP6 | 2 | C20 | 72 | hr | 2543 | 1108 | 5578 | 0.1986 | -0.4729 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP6 | 3 | C20 | 72 | hr | 2543 | 1111 | 5578 | 0.1992 | -0.4720 |
| SK-BR-3 | MK2206 | 3.33 | uM | LJP6 | 1 | F02 | 72 | hr | 2543 | 3292 | 5578 | 0.5901 | 0.2466 |
| SK-BR-3 | MK2206 | 3.33 | uM | LJP6 | 2 | F02 | 72 | hr | 2543 | 3106 | 5578 | 0.5568 | 0.1853 |
| SK-BR-3 | MK2206 | 3.33 | uM | LJP6 | 3 | F02 | 72 | hr | 2543 | 3031 | 5578 | 0.5433 | 0.1606 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 1 | A14 | 72 | hr | 2543 | 1344 | 5578 | 0.2409 | -0.3952 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 2 | A14 | 72 | hr | 2543 | 1270 | 5578 | 0.2277 | -0.4196 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 3 | A14 | 72 | hr | 2543 | 1578 | 5578 | 0.2829 | -0.3181 |
| SK-BR-3 | Nilotinib | 3.33 | uM | LJP5 | 1 | N14 | 72 | hr | 2543 | 6221 | 5578 | 1.1151 | 1.2116 |
| SK-BR-3 | Nilotinib | 3.33 | uM | LJP5 | 2 | N14 | 72 | hr | 2543 | 6016 | 5578 | 1.0784 | 1.1441 |
| SK-BR-3 | Nilotinib | 3.33 | uM | LJP5 | 3 | N14 | 72 | hr | 2543 | 5962 | 5578 | 1.0687 | 1.1263 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 1 | H02 | 72 | hr | 2543 | 4384 | 5578 | 0.7859 | 0.6064 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 2 | H02 | 72 | hr | 2543 | 4516 | 5578 | 0.8095 | 0.6499 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 3 | H02 | 72 | hr | 2543 | 4536 | 5578 | 0.8131 | 0.6565 |
| SK-BR-3 | NU7441 | 3.33 | uM | LJP5 | 1 | C08 | 72 | hr | 2543 | 4310 | 5578 | 0.7726 | 0.5820 |
| SK-BR-3 | NU7441 | 3.33 | uM | LJP5 | 2 | C08 | 72 | hr | 2543 | 4950 | 5578 | 0.8873 | 0.7929 |
| SK-BR-3 | NU7441 | 3.33 | uM | LJP5 | 3 | C08 | 72 | hr | 2543 | 4700 | 5578 | 0.8425 | 0.7105 |
| SK-BR-3 | Dactolisib | 3.33 | uM | LJP5 | 1 | M14 | 72 | hr | 2543 | 2128 | 5578 | 0.3815 | -0.1369 |
| SK-BR-3 | Dactolisib | 3.33 | uM | LJP5 | 2 | M14 | 72 | hr | 2543 | 2039 | 5578 | 0.3655 | -0.1662 |